Size | Price | |
---|---|---|
100mg | ||
250mg | ||
500mg | ||
Other Sizes |
Targets |
Caspase-3 Caspase-9
|
---|---|
ln Vitro |
In comparison to normal human cell lines, ganoderic acid Mk (0-100 μM, 24 h) displays greater cytotoxicity against human cancer cells [1]. HeLa cell growth is dose-dependently inhibited by ganoderic acid Mk (0–40 μM, 12-48 h) [1]. HeLa cells undergo apoptosis when exposed to gonadoderic acid Mk (0–40 μM, 24 h)[1]. Ganoderic acid Mk (0-40 μM, 24 h) causes a rise in caspase-3 and -9 activity, a reduction in MMP, and a burst of ROS [1].
|
Cell Assay |
Cell Cytotoxicity Assay[1]
Cell Types: Human normal cell lines (MCF-10A and HF) and cancer cell lines (HO- 8910PM, SW1990, 95-D and HeLa) Tested Concentrations: 0-100 μM Incubation Duration: 24 h Experimental Results: demonstrated stronger cytotoxicity to human cancer cells (IC50 values were ranged within 29.8-44.2 µM) than human normal cell lines (IC50 values to MCF-10A and HF were 84.5 µM and 78.4 µM, respectively). Cell Viability Assay[1] Cell Types: HeLa cells Tested Concentrations: 0, 5, 10, 20, 40 μM Incubation Duration: 12, 24, 48 h Experimental Results: demonstrated cytotoxicity on HeLa cells in a dose- and time-dependent manner. Apoptosis Analysis[1] Cell Types: HeLa cells Tested Concentrations: 0, 10, 20, 40 μM Incubation Duration: 24 h Experimental Results: Increased the rate of early and late apoptotic cells in a dose-dependent manner in HeLa cells. GA-Mk could induce HeLa cells apoptosis in parallel with the accumulation of ROS, the loss of MMP and the activation of activities of caspases. |
References |
[1]. Liu R M, et al. Anti-proliferation and induced mitochondria-mediated apoptosis of ganoderic acid Mk from Ganoderma lucidum mycelia in cervical cancer HeLa cells[J]. Latin American Journal of Pharmacy, 2012, 31(1):43-50.
[2]. Ding N, et al. Separation and determination of four ganoderic acids from dried fermentation mycelia powder of Ganoderma lucidum by capillary zone electrophoresis. J Pharm Biomed Anal. 2010 Dec 15;53(5):1224-30. |
Molecular Formula |
C34H50O7
|
---|---|
Molecular Weight |
570.76
|
CAS # |
110024-14-1
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
CNC1CN=C(C2=CC=CN2)C2=CC(=CC=C2N=1)Cl
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.7520 mL | 8.7602 mL | 17.5205 mL | |
5 mM | 0.3504 mL | 1.7520 mL | 3.5041 mL | |
10 mM | 0.1752 mL | 0.8760 mL | 1.7520 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.